Related content

The population attributable fraction as a measure of the impact of warfarin pharmacogenetic testing

By Chan Sze Ling   Suo Chen   Chia Kee Seng   Teo Yik Ying  

Pharmacogenomics, Vol. 13, Iss. 11, 2012-08 ,pp. : 1247-1256

Future Medicine

Access to resources Recommend Favorite

Concomitant roxithromycin use among elderly patients taking warfarin resulting in significant over‐anticoagulation

By  

JOURNAL OF PHARMACY PRACTICE AND RESEARCH, Vol. 45, Iss. 4, 2015-12 ,pp. : 486-486

John Wiley & Sons Inc

Access to resources Recommend Favorite

Anticoagulation Control in Hospitalised Patients on Warfarin

By  

JOURNAL OF PHARMACY PRACTICE AND RESEARCH, Vol. 38, Iss. 4, 2008-12 ,pp. : 292-295

John Wiley & Sons Inc

Access to resources Recommend Favorite

Validation of warfarin pharmacogenetic algorithms in clinical practice

By Marin-Leblanc Mélina   Perreault Sylvie   Bahroun Imen   Lapointe Mathieu   Mongrain Ian   Provost Sylvie   Turgeon Jacques   Talajic Mario   Brugada Ramon   Phillips Michael   Tardif Jean-Claude   Dubé Marie-Pierre  

Pharmacogenomics, Vol. 13, Iss. 1, 2012-01 ,pp. : 21-29

Future Medicine

Access to resources Recommend Favorite

Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European––Americans and African––Americans

By Limdi Nita A   Arnett Donna K   Goldstein Joyce A   Beasley T Mark   McGwin Gerald   Adler Brian K   Acton Ronald T  

Pharmacogenomics, Vol. 9, Iss. 5, 2008-05 ,pp. : 511-526

Future Medicine

Access to resources Recommend Favorite